Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Kymera Therapeutics Inc KYMR

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small... see more

Recent & Breaking News (NDAQ:KYMR)

Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4

GlobeNewswire December 13, 2023

Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

GlobeNewswire December 10, 2023

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

GlobeNewswire December 7, 2023

Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine

GlobeNewswire November 13, 2023

Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting

GlobeNewswire November 2, 2023

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire November 2, 2023

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire November 1, 2023

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

GlobeNewswire October 27, 2023

Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2

GlobeNewswire October 26, 2023

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

GlobeNewswire October 16, 2023

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

GlobeNewswire September 18, 2023

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire August 28, 2023

Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire August 3, 2023

Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3

GlobeNewswire July 27, 2023

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

GlobeNewswire June 22, 2023

Kymera Therapeutics' STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

GlobeNewswire June 14, 2023

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

GlobeNewswire June 9, 2023

Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress

GlobeNewswire June 9, 2023

Kymera Therapeutics to Participate in Upcoming June Investor Conference

GlobeNewswire June 1, 2023

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

GlobeNewswire May 22, 2023